According to a number of studies, SCD1 inhibitors in ovarian cancer can dramatically increase the effect of ferroptosis and aid in tumor cell regression, in addition to increasing the sensitivity of ferroptosis inducers. This evidence concerns the gene SCD and ovarian carcinoma.